Examkin

Soru

Zorluk: ZorSubstance-Related and Addictive Disorders

Match each pharmacotherapy used in the treatment of substance-related and addictive disorders to its primary mechanism of action, key clinical consideration, or contraindication.

  • AcamprosateModulates glutamatergic tone via NMDA receptor antagonism; contraindicated in patients with severe renal impairment.
  • VareniclinePartial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors; frequently associated with nausea and abnormal dreams.
  • BuprenorphineHigh-affinity partial mu-opioid receptor agonist; can precipitate acute withdrawal if administered to a patient with full agonists in their system.
  • NaltrexoneCompetitive mu-opioid receptor antagonist; requires a 7 to 14-day period of complete opioid abstinence prior to initiation.
  • MethadoneLong-acting full mu-opioid receptor agonist; necessitates baseline and ongoing electrocardiogram monitoring due to the risk of QTc prolongation.

Cevap

Acamprosate matches with the renal contraindication; Varenicline matches with the nicotinic partial agonist mechanism and vivid dreams; Buprenorphine matches with the high-affinity partial agonist mechanism capable of precipitating withdrawal; Naltrexone matches with the competitive antagonist requiring opioid abstinence; Methadone matches with the full agonist requiring QTc monitoring.
Each major pharmacotherapy for substance use disorders possesses distinct receptor interactions, adverse effect profiles, and metabolic pathways that govern clinical decision-making. Acamprosate is unique in being renally cleared, avoiding hepatotoxicity. Varenicline targets nicotinic receptors to reduce cravings but causes vivid dreams. Buprenorphine's high receptor affinity allows it to displace full agonists, which can precipitate withdrawal. Naltrexone completely blocks opioid receptors and requires a completely opioid-free system to prevent severe withdrawal. Methadone acts as a full agonist and carries a specific risk for QTc prolongation, necessitating cardiac monitoring.

Adım Adım Çözüm

1
Identify the mechanism and primary clearance route for Acamprosate.
Matched with NMDA modulation and renal contraindication.
Acamprosate is uniquely renally excreted among alcohol use disorder medications, making severe renal impairment its primary contraindication.
2
Identify the mechanism and common side effects of Varenicline.
Matched with nicotinic partial agonism, nausea, and abnormal dreams.
Varenicline specifically targets nicotinic receptors for tobacco use disorder and characteristically causes vivid dreams.
3
Differentiate the opioid use disorder medications based on receptor affinity and intrinsic activity.
Buprenorphine matched with partial agonism and precipitated withdrawal risk.
Buprenorphine's high affinity but partial agonism causes it to displace full agonists, precipitating withdrawal if patients are not already in mild withdrawal.
4
Identify the medication requiring prolonged abstinence prior to initiation.
Naltrexone matched with competitive antagonism requiring 7-14 days of abstinence.
As a pure antagonist, naltrexone will induce severe withdrawal if any opioids remain in the patient's system.
5
Identify the major safety monitoring requirement for Methadone.
Matched with full agonism and QTc prolongation risk.
Methadone is unique among these agents for its significant risk of dose-dependent QTc prolongation, requiring baseline and periodic ECGs.

Anahtar Kavram

Pharmacotherapy for Substance-Related and Addictive Disorders
Bu soruyu puanla

Konular

Substance-Related and Addictive Disorders

Bu konudan daha fazla soru